Lymphatic System Assessment Before Immune Cancer Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Patients with dysregulated lymphatic systems do not respond to immune-modulating therapies, leading to rapid tumor progression and poor overall survival, as these therapies depend on immune cell priming, antigen presentation, or antigen trafficking, and existing treatments fail to address established metastatic disease after primary tumor removal.

Innovation Solution

Administer a therapeutic amount of a drug to regulate the dysregulated lymphatic system and an immune-modulating therapy that operates independently of immune-cell priming, antigen trafficking, and antigen presentation, using VEGFR-3 and VEGFR-2 antagonists in combination with immune checkpoint inhibitors to treat cancer.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immune-modulating therapy is administered to patients with dysregulated lymphatic systems, then immune cell priming and antigen presentation are enhanced, but the therapy fails to produce response due to lymphatic dysfunction

Engineering Contradiction:

Improvetherapy response rateVSAvoidlymphatic system function

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies preliminary action by administering lymphatic regulatory therapy before immune-modulating therapy to correct the underlying lymphatic dysfunction. This preparatory step ensures the lymphatic system is functional before introducing therapies that depend on it, thereby preventing treatment failure.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses lymphatic regulatory therapy as an intermediary treatment that bridges the gap between lymphatic dysfunction and immune therapy effectiveness. This intermediary therapy corrects the lymphatic system's function, enabling subsequent immune-modulating therapies to work as intended.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If conventional immune-modulating therapies are used in patients with lymphatic invasion or lymphangitic carcinomatosis, then treatment simplicity is maintained, but immune cell activation and priming fail to occur

Engineering Contradiction:

Improvetreatment simplicityVSAvoidimmune cell activation

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent implements preliminary action by first assessing lymphatic system status and administering lymphatic regulatory therapy before proceeding with immune-modulating therapy. This two-step approach ensures that the lymphatic system is corrected beforehand, enabling reliable immune cell activation while maintaining overall treatment feasibility.

Inventive Principle:

Principle #10Preliminary action

3Productivity

If immune-modulating therapy is administered without assessing lymphatic system status, then treatment speed is maintained, but patient response cannot be predicted

Engineering Contradiction:

Improvetreatment speedVSAvoidpatient response prediction

Core Design Contradiction:

ProductivityVSMeasurement precision

Solution Approach 1:

The patent applies preliminary action by implementing lymphatic system assessment and regulation before immune therapy administration. This preliminary evaluation step enables accurate prediction of patient response while maintaining efficient treatment delivery through streamlined protocols.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12460003B2Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems

Publication Date: 2025.11.04 ENSEMBLE GRP HLDG

AI summary

Provided herein is a method for determining cancer treatment using an immune-modulating therapy in a subject in need thereof. The method comprises assessing whether a lymphatic system in a subject is dysregulated. When the lymphatic system is dysregulated, a treatment for the lymphatic system is determined before a therapeutic amount of an immune-modulating therapy is administered to treat cancer in the subject. Alternatively, when the lymphatic system is dysregulated, an immune-modulating therapy is selected to treat cancer in the subject. The immune-modulating therapy is independent of immune-cell priming, antigen trafficking, antigen presentation, and any combination thereof. The subject may also be treated for cancer accordingly.